Market reactionShares rose 11% on Nov 4.
ADC Therapeutics sells ZYNLONTA, an antibody-drug conjugate with accelerated approval for diffuse large B-cell lymphoma after two or more prior treatments, and is testing it in earlier lines.
ZYNLONTA remains commercially available under accelerated approval in later-line DLBCL, but FDA’s LOTIS-5 benefit-risk concerns cloud full approval and earlier-line expansion. LOTIS-7 with glofitamab and planned Phase 3 trials underpin growth ambitions. The agreed financing and restructuring support management’s expected runway into 2029, conditional on closing. Tanabe’s Japan application adds a partnered expansion opportunity, with filing acceptance and first commercial sale named as license milestones.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: LOTIS-7 supports a combination Phase 3
Do the full LOTIS-7 data support durable responses and acceptable safety for ZYNLONTA plus glofitamab?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
FDA concerns persist; LOTIS-7 remains the main growth decision as Japan application advances
LOTIS-5 met its PFS endpoint, but FDA's mortality concern shifts the expansion case to LOTIS-7 and a new registrational path
ZYNLONTA's Phase 3 win is clouded by a near-tripled Grade 5 death rate; FDA benefit-risk judgment determines whether label expansion holds
ZYNLONTA's LOTIS-5 Phase 3 PFS readout will determine whether a CD19 ADC can expand from 3L+ salvage to a competitive 2L+ DLBCL standard of care
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Blood cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
4 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.